EDGAR Filing Documents for 0001193125-20-024920

Form 8-K - Current report:

SEC Accession No. 0001193125-20-024920

Filing Date

2020-02-05

Accepted

2020-02-05 08:31:42

Documents

Period of Report

2020-02-04

Items

Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Interactive Data

Document Format Files

Seq	Description	Document	Type	Size
1	8-K	d883455d8k.htm iXBRL	8-K	73848
2	EX-3.1	d883455dex31.htm	EX-3.1	89555
3	EX-4.1	d883455dex41.htm	EX-4.1	95165
4	EX-4.2	d883455dex42.htm	EX-4.2	30014
5	EX-10.1	d883455dex101.htm	EX-10.1	132052
6	EX-10.2	d883455dex102.htm	EX-10.2	473919
7	EX-10.3	d883455dex103.htm	EX-10.3	287428
11	GRAPHIC	g883455g0205100258834.jpg	GRAPHIC	3405
	Complete submission text file	0001193125-20-024920.txt		1608907

Data Files

Seq	Description	Document	Type	Size
8	XBRL TAXONOMY EXTENSION SCHEMA	aimt-20200204.xsd	EX-101.SCH	3066
9	XBRL TAXONOMY EXTENSION LABEL LINKBASE	aimt-20200204_lab.xml	EX-101.LAB	18889
10	XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE	aimt-20200204_pre.xml	EX-101.PRE	11857
19	EXTRACTED XBRL INSTANCE DOCUMENT	d883455d8k_htm.xml	XML	3566

Mailing Address 8000 MARINA BOULEVARD SUITE 300 BRISBANE CA 94005-1884

Business Address 8000 MARINA BOULEVARD SUITE 300 BRISBANE CA 94005-1884 (650) 614-5220

Aimmune Therapeutics, Inc. (Filer) CIK: 0001631650 (see all company filings)